T
Entrada Therapeutics, Inc.
TRDA · NASDAQ · Healthcare · 290M
Price · close
$7.57
-0.39% · last session
Graham & Buffett's criteria
published figures · last financial year
Price / earningsP/E
—
Price / net assetsP/B
1.0×
Enterprise value / EBITDAEV/EBITDA
-1.9×
Free cash flow yieldFCF yield
-41.4%
Return on equityROE
-47.0%
Operating margin
-613.7%
Net debt / EBITDAbalance-sheet strength
0.3×
Interest coverage
—
How we read it
an educational summary · not advice
Figures provided for information and education — they do not constitute personalized investment advice. Investing carries a risk of capital loss.